Suggestions
Jane Rho
Director, Fund & AI | DaVita
Jane Rho is a prominent figure in the healthcare investment sector, currently serving as a Board Observer at Dock Health. She is also the Director of the Venture Fund at DaVita Venture Group, where she leads investments in early-stage healthcare startups, particularly in tech-enabled services and digital health.12
Educational Background
Jane Rho holds a Master of Public Health (MPH) from Harvard University and a Bachelor of Arts (HBA) from the Ivey Business School, equipping her with a strong foundation in both public health and business.1
Professional Experience
Before her current roles, Rho gained valuable experience as a management consultant at Bain & Company and worked at Massachusetts General Hospital. She has also been involved in founding a digital health startup and has collaborated with several other healthcare startups.12
Additional Information
In addition to her role at Dock Health, Jane Rho has been associated with DaVita Kidney Care and Heartbeat Health, further broadening her expertise in the healthcare landscape.23 Her diverse background highlights her commitment to fostering innovation within the healthcare sector.
Highlights
Warren Buffett released that Greg Abel will be his successor to replace him as CEO of Berkshire Hathaway, but the most exciting part of this announcement to me is that Greg is from none other than Edmonton, Alberta. I grew up in this relatively underrated and overly frigid city of Edmonton, where I made lasting friendships, memories, and early professional experiences.
I love reading about the continuing growth of the Canadian investment and innovation ecosystem- one that holds tremendous talent and character. Looking forward to seeing what continues to emerge from the humble province of Alberta and city of Edmonton.
https://lnkd.in/gEwRrq7f
Alberta Innovates City of Edmonton
#canada #alberta #edmonton #berkshire #GregAbel
Excited to join others at the MedCity INVEST conference in May to judge the healthtech track focused on payers/providers with Dipa Mehta and Jasmi Shah!
Often, I'm asked whether our investment scope at DaVita Venture Group is restricted to kidney-related companies. The short answer is "no."
We think about broader investment categories including areas such as:
- cardiometabolic care (e.g., our investment in the virtual cardiology player, Heartbeat Health)
- patient engagement (e.g., our port cos Wellth, SameSky Health)
- physician collaboration (e.g., our awesome partner Dock Health)
- continuum of care (e.g., our supportive care port co Vynca)
- in-home care- no investment yet, but we're actively looking
- AI- looking at a lot here, but have a bias partnering with and backing scaled players addressing use cases with tangible ROI
- and many other categories!
Check out more in a write-up I provided MedCity News at the link/below!
"DaVita Venture Group serves as the growth and innovation arm of DaVita, a healthcare provider focused on transforming care delivery to improve quality of life for patients with chronic kidney disease globally. We look at opportunities to innovate care for polychronic patients and improve the holistic care experience beyond the kidneys by investing in new innovations adjacent to the kidney.
In the past few years, we’ve developed more flexibility to look at later-stage companies that have more traction and could create larger scale collaborations with our organization. Our team has worked to understand and proactively identify prospective partners that could add value to DaVita and support our commitment to transforming the care experience. Our team looks across tech-enabled services, digital health, and diagnostics that serve patients, our teammates, and independent physicians."
https://lnkd.in/gEu9nGPa
